
Novo joins forces with MIT innovating drug devices
pharmafile | September 8, 2015 | News story | Manufacturing and Production, Research and Development | Novo Nordisk
Novo Nordisk has initiated a research collaboration with the Langer Laboratory at the Massachusetts Institute of Technology for what is thought to be the next generation of drug delivery devices for the administration of peptides.
The aim of the research collaboration, which is conducted at both MIT in Boston, US and at Novo Nordisk’s research facilities in Måløv and Hillerød, Denmark, is to develop the next generation of drug delivery devices as an alternative to parenteral or injection-based delivery of peptides.
Peter Kurtzhals, senior vice president and head of global research at Novo Nordisk says: “Drug delivery devices hold great potential and I am looking forward to this exciting research collaboration with one of the world’s leading drug delivery laboratories,”
Professor Robert Langer’s laboratory at MIT are world-leading experts in creating new approaches for delivering drugs such as peptides and proteins across complex barriers in the body such as the blood-brain barrier, the intestine, the lung and the skin. Together with Dr Giovanni Traverso, a gastroenterologist and biomedical engineer at Harvard Medical School, and research affiliate of MIT, they will lead a team in the development of a platform enabling the oral delivery of peptides.
Robert Langer, professor and head of the Langer Laboratory at MIT, says: “We are very excited to be doing research sponsored by Novo Nordisk to address one of the current greatest challenges in drug delivery”.
Yasmita Kumar
Related Content

FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …

BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …

Pila Pharma raises SEK 20m to advance new oral obesity treatment
Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital …






